Immunome (IMNM) EBITDA Margin (2023 - 2025)

Immunome (IMNM) has 3 years of EBITDA Margin data on file, last reported at 1157.61% in Q2 2025.

• Quarterly EBITDA Margin rose 53482.0% year-over-year to 1157.61% in Q2 2025, while the trailing twelve-month figure through Mar 2026 was 5947.9% (down 395359.0% YoY) and the FY2025 annual result came in at 3228.83%, up 15354.0% from the prior year.
• EBITDA Margin advanced to 1157.61% in Q2 2025, from 1525.5% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 129.96% in Q3 2023 to a low of 12857.05% in Q1 2024.
• A 3-year average of 2492.75% and a median of 1608.96% in 2025 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2024 — EBITDA Margin plunged 1266792 bps — and 2025, when it surged 1133155 bps.
• Tracing IMNM's EBITDA Margin over 3 years: stood at 2473.94% in 2023, then decreased by 22 bps to 3030.31% in 2024, then soared by 62 bps to 1157.61% in 2025.
• The last three EBITDA Margin figures came in at 1157.61% (Q2 2025), 1525.5% (Q1 2025), and 3030.31% (Q4 2024), per Business Quant data.